Related Experiment Video
Updated: Mar 9, 2026
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
Published on: March 3, 2015
Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis
Galina Semenova1, Dina S Stepanova2, Sergey M Deyev3
1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Abstract:
The variable manifestation of phenotypes that occur in patients with neurofibromatosis type 1 (NF1) includes benign and malignant neurocutaneous tumors for which no adequate treatment exists. Cell-based screening of known bioactive compounds library identified the protein phosphatase 2A (PP2A) inhibitor Cantharidin and the L-type calcium channel blocker Nifedipine as potential candidates for NF1 pharmacotherapy. Validation of screening results using human NF1-associated malignant peripheral nerve sheath tumor (MPNST) cells showed that Cantharidin effectively impeded MPNST cell growth, while Nifedipine treatment significantly decreased local tumor growth in an MPNST xenograft animal model. These data suggest that inhibitors of PP2A, as well as calcium channel blockers, might be used in broader MPNST preclinical studies as single agents or in combinatorial therapeutic strategies.
Insights
Researchers identified two compounds, Cantharidin and Nifedipine, as potential treatments for neurofibromatosis type 1 (NF1) tumors. Cantharidin inhibited MPNST cell growth, and Nifedipine reduced tumor growth in animal models, suggesting new therapeutic strategies.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Neurofibromatosis type 1 (NF1) presents with diverse phenotypes, including neurocutaneous tumors with limited treatment options.
- Malignant peripheral nerve sheath tumors (MPNST) are aggressive NF1-associated malignancies requiring novel therapeutic approaches.
Purpose of the Study:
- To identify potential pharmacotherapies for NF1-associated tumors through compound library screening.
- To validate the efficacy of identified compounds, Cantharidin and Nifedipine, against MPNST.
Main Methods:
- Cell-based screening of a bioactive compound library.
- In vitro validation using human MPNST cells.
- In vivo assessment using an MPNST xenograft animal model.
Main Results:
- Cantharidin, a protein phosphatase 2A (PP2A) inhibitor, effectively impeded MPNST cell growth.
- Nifedipine, an L-type calcium channel blocker, significantly decreased tumor growth in an MPNST xenograft model.
- Both compounds demonstrated potential as single agents or in combination therapies.
Conclusions:
- PP2A inhibitors and calcium channel blockers represent promising therapeutic avenues for NF1-associated MPNST.
- Further preclinical studies are warranted to explore these agents in combinatorial strategies for NF1 pharmacotherapy.
More Related Videos
10:30A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
08:43A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
Published on: March 10, 2017
